



Original Article

In vitro-in vivo Pharmacokinetic correlation model for quality assurance of antiretroviral drugs

Modelo de correlación farmacocinético *in vitro-in vivo* para el aseguramiento de la calidad de medicamentos antirretrovirales

Ricardo Rojas Gómez, Piedad Restrepo Valencia

Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM), Cali, Colombia.

Rojas GR, Restrepo VP. *In vitro-in vivo Pharmacokinetic correlation model for quality assurance of antiretroviral drugs. Colomb Med. 2015; 46(3): 109-16.*

© 2015. Universidad del Valle. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Article history:

Received: 09 July 2014
Revised: 06 March 2015
Accepted: 20 August 2015

Keywords:

Antiretrovirals,
permeability, dissolution,
pharmacokinetics,
bioavailability, correlation.

Palabras clave:

antirretrovirales,
permeabilidad, disolución,
farmacocinética,
biodisponibilidad,
correlación.

Abstract

Introduction: The *in vitro-in vivo* pharmacokinetic correlation models (IVIVC) are a fundamental part of the drug discovery and development process. The ability to accurately predict the *in vivo* pharmacokinetic profile of a drug based on *in vitro* observations can have several applications during a successful development process.

Objective: To develop a comprehensive model to predict the *in vivo* absorption of antiretroviral drugs based on permeability studies, *in vitro* and *in vivo* solubility and demonstrate its correlation with the pharmacokinetic profile in humans.

Methods: Analytical tools to test the biopharmaceutical properties of stavudine, lamivudine y zidovudine were developed. The kinetics of dissolution, permeability in caco-2 cells and pharmacokinetics of absorption in rabbits and healthy volunteers were evaluated.

Results: The cumulative areas under the curve (AUC) obtained in the permeability study with Caco-2 cells, the dissolution study and the pharmacokinetics in rabbits correlated with the cumulative AUC values in humans. These results demonstrated a direct relation between *in vitro* data and absorption, both in humans and in the *in vivo* model.

Conclusions: The analytical methods and procedures applied to the development of an IVIVC model showed a strong correlation among themselves. These IVIVC models are proposed as alternative and cost/effective methods to evaluate the biopharmaceutical properties that determine the bioavailability of a drug and their application includes the development process, quality assurance, bioequivalence studies and pharmacosurveillance.

Resumen

Introducción: Los modelos de correlación *In vitro-in vivo* (IVIVC) son parte integral del proceso de investigación y desarrollo de fármacos. La capacidad de predecir con exactitud el perfil *in vivo* a partir de las observaciones *in vitro* tiene diversas aplicaciones durante el desarrollo exitoso de una formulación.

Objetivo: Desarrollar un modelo integral para predecir la absorción *in vivo* de fármacos antirretrovirales con base en estudios de permeabilidad, solubilidad *in vitro* e *in vivo* y demostrar su correlación con la farmacocinética en humanos.

Métodos: Se desarrollaron y validaron las técnicas bioanalíticas para valorar las propiedades biofarmacéuticas de Estavudina, Lamivudina y Zidovudina. Se evaluó las cinéticas de disolución, la permeabilidad en monocapas celulares Caco-2 y la farmacocinética de absorción *in vivo* en conejos y voluntarios sanos.

Resultados: Los valores de AUC acumulados en el sistema de células Caco-2, en la disolución y en el modelo animal, fueron correlacionados con los valores de AUC acumulados en el humano. Con lo anterior se demostró una relación directamente proporcional entre los resultados *in vitro* con respecto a los obtenidos en la fase de absorción tanto en el humano como en el modelo animal.

Conclusiones: Los métodos analíticos y procedimientos aplicados en la IVIVC demostraron las correspondencias directas entre sí, con altos niveles de correlación. Se proponen estos modelos IVIVC como métodos alternativos costo/efectivos para la valoración de las propiedades biofarmacéuticas que determinan la biodisponibilidad, en el desarrollo de productos, en el aseguramiento de la calidad y como pruebas de bioequivalencia en los programas de farmacovigilancia.

Corresponding author:

Ricardo Rojas Gómez. Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM), Carrera 125 No 19-225, AA 5390, Cali, Colombia. E-mail: rrojas@cideim.org.co.

Introduction

The *in vitro-in vivo* pharmacokinetic correlation models (IVIVC) are a fundamental part of the drug discovery and development process. These models can accurately predict the *in vivo* behavior of drugs based on *in vitro* observations, and their applications include: pharmacokinetic properties testing, quality assurance, pharmacosurveillance and quality control during the development and scale up of a formulation. Correlation is defined, according to the United States Food and Drug Administration (FDA), as “a predictive mathematical model describing the relationship between an *in vitro* property of a dosage form and an *in vivo* response”. The property of solid dosage forms most commonly applied for *in vitro* development and quality control tests is the rate of dissolution of the drug and it is usually correlated with the concentration or amount of drug absorbed that reach the plasma circulation at certain time¹. Therefore, an IVIVC model based on dissolution tests allows to predict the *in vivo* behavior of some drugs.

Even though the correlation between *in vitro* dissolution and *in vivo* absorption has been recognized, no many comprehensive models that include complementary properties to improve the predictive capacity have been developed. Comprehensive models are required taking into account the physical, chemical and biological factors involve in the dissolution and absorption of drugs. The physicochemical and biopharmaceutical properties of the drug and the physiology of the routes of absorption have to be taken into consideration.

The solubility is determined by factors like the percentage of ionized drug, which determines different properties of the compounds, depending on the pH at the site of dissolution. This is very relevant because the human body displays pH gradients, especially in the gastrointestinal tract (GI), this pH gradient leads to differences in the absorption profile depending on the *in vivo* pH².

The goal of this study was to develop a comprehensive model to predict the *in vivo* pharmacokinetic behavior of antiretroviral drugs at the absorption phase, based on *in vitro* permeability and solubility measurements. The rationale behind this study is set in the current context where advances in the pharmaceutical sciences, the pharmaceutical industry and the government health agencies have consolidated the quality assessment of pharmaceutical products by *in vivo* bioavailability studies in humans. However, the financial and ethical implications of these studies require the development of alternatives that can substitute the use of humans. These alternatives should consider the physicochemical properties and permeability of the molecules, according to the Biopharmaceutics Classification System (BCS)³.

Materials and Methods

Reagents

The analytical standards and dosage forms of stavudine (d4T), lamivudine (3TC) and zidovudine (AZT) were provided by Humax Pharmaceutical (Medellin, Colombia). Dulbecco's modified Eagle's medium (DMEM) supplemented with L-Glutamine, nonessential amino acids (NEA 100X), Hanks balanced salt solution (HBSS),

(N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]) sodium salt (HEPES), sodium bicarbonate and penicillin/streptomycin 100X were purchase form Sigma-Aldrich. Fetal bovine serum was purchased from Gibco and all the reagents were prepared in accordance with supplier instructions.

Dissolution

The kinetics of *in vitro* dissolution were performed following the specifications of the United States Pharmacopeia, using the dissolution apparatus 2 (Pharma Alliance Group, Model TDT-08L). The rotation was set at 50 rpm, the dissolution media was degassed water at a final volume of 900 mL and a temperature of 37° C ± 0.5. Samples were taken at 10, 20, 30, 45 y 60 min.

Caco-2 cells culture

Caco-2 cells (HTB-37) were obtained from the American Type Culture Collection (ATCC). Cells were used between 30 and 50 passes in high glucose (4.5 g/L) DMEM media supplemented with L-Glutamine, 10% fetal bovine serum, 1% nonessential amino acids and 1% penicillin/streptomycin. For the permeability test, 6x10⁴ cells/cm² were seeded in *transwell* supports with polycarbonate membrane (0.4 µm, 1.12 cm²; Corning Costar). The integrity of the monolayers was tested by measuring the Transepithelial Electrical Resistance (TEER) before and after every experiment. Only monolayers with TEER higher than 200 Ω/cm² were used.

The apparent permeability coefficient (P_{app}) was determined from the amount of drug transported per unit of time and was calculated using the following equation:

$$P_{app} = \frac{\left(\frac{\Delta Q}{\Delta t}\right)}{(AxCo)}$$

Where (ΔQ/Δt) is the accumulated concentration in the recipient compartment (µmol/sec) versus the change in time, A is the surface area of the support (cm²) and C₀ is the initial concentration in the donor compartment (µM). The integrity of the system was evaluated using the permeability coefficient (P). The apparent permeability coefficient (P_{app}) is associated with the permeability coefficient.

$$P = \left(\frac{\Delta Q}{\Delta t}\right) \times \left(\frac{\text{Recipient compartment concentration}}{\text{Transwell support area}}\right)$$

Pharmacokinetics in animals

All protocols and procedures were reviewed and approved by CIDEIM Institutional Review Board for research involving animals, in accordance with national and international guidelines for utmost respect and care of animals, recognizing their intrinsic value as living species, as well as deep reflection on the possibilities of replacement, reduction and refinement of techniques and procedures⁴⁻⁶. In every pharmacokinetic study 10 New Zealand rabbits were included per group, their weights were between 2.5-3.2 kg. Rabbits were kept at the animal facility under all standard conditions for the handling (20-25° C; 30-70% relative humidity, natural cycle of light/dark), with access to water and food *ad libitum* up to 2 hours before the study and one hour after the administration of the drug as an oral aqueous suspension. Each group received a single dose of stavudine 8.9 mg/kg, lamivudine 20.8 mg/kg or zidovudine 41.7 mg/kg. Two milliliters blood samples were taken from the marginal ear vein, before the administration

of the drug and up to 6 hours after administration, at the following time points for lamivudine and zidovudine: 0.0, 0.25, 0.5, 0.75, 1.0, 2.0, 3.0, 4.0 and 6.0 h. For stavudine, samples were collected up to 3 hours after the administration at 0.0, 0.08, 0.17, 0.25, 0.33, 0.5, 0.75, 1.0, 2.0 and 3 h. Samples were centrifuged at 1,500 rpm for 20 min and plasma was analyzed by high performance liquid chromatography (HPLC) for the quantification of each active pharmaceutical ingredient (API).

Pharmacokinetics in humans

The study and the protocols were approved by CIDEIM Institutional Review Board for research, in accordance with the Declaration of Helsinki (October 2008), the International ethical guidelines for research involving human subjects of the Council for International Organizations of Medical Sciences (CIOMS) and the Colombian Ministry of Social Protection Resolution 2378 from 2008. This study was designed as a randomized, open-label, one-way, one sequence and single-dose study. The participants of the study were 18-35 yrs old males, between $\pm 15\%$ ideal weight, healthy according to the physical examination and the laboratory tests (serum biochemistry, hematology, hepatic function, renal function, thyroid function and urinalysis). After explanation of the study risk and procedures, voluntary, informed, signed consent was provided by each participant. Ten volunteers received a single capsule of stavudine 40 mg (Humax Pharmaceutical) and the second group of 9 volunteers received a single combined tablet of lamivudine 150 mg/zidovudine 300 mg (Humax pharmaceutical) with 240 mL of water. Blood samples (8 mL) were collected before and up to 12 h after the administration of the drug, from a catheter maintained with saline solution. The sampling intervals were: 0.0, 0.17, 0.33, 0.50, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 9.0 and 12 h.

Sample analysis

Human and rabbit plasma samples were analyzed using a UPLC apparatus equipped with UV diode array detector (LaChrome Ultra, Hitachi). Samples were injected onto a Chromolith® Performance RP-18 column (100x4.6 mm, Merck), using a mobile phase containing 10 mM ammonium acetate buffer and acetonitrile (96:4, pH 6.0) at 35° C. The flow rate was 1.2 mL/min. Plasma proteins were precipitated with methanol and the procedure was validated according to FDA guidelines⁷.

Statistical analysis

Pharmacokinetic parameters were calculated using non-compartmental methods, with log transformation of concentration data. The elimination half-life ($t_{1/2}$) was estimated from the linear regression of the concentration curve versus time. The area under the plasma concentration curve versus time was determined by the trapezoidal method using the PK Solutions Pharmacokinetics Data Non-compartmental Analysis® software (Summit Research Services, Windows 2.0.6 Excel 2002 Edition). Statgraphics® Plus

4.1. Professional Version (Statistical Graphics Corp) was used for the validation of bioanalytical methods and linearity calculations.

Results

Development and validation of bioanalytical methods

The methods for identification and quantification of stavudine, lamivudine and zidovudine were developed in plasma for the pharmacokinetic studies and in HBSS for permeability tests. To validate the methods, calibration curves were made by preparing ten different dilutions of the standards (five replicates per concentration) in HBSS or drug free plasma. The linearity was evaluated in the range of 0.25 to 6.0 g/mL for d4T and 3TC, and 0.25 to 8.0 g/mL for AZT. The standards prepared in HBSS and plasma were stable for more than 90 days at -75° +/- 5° C. All methods met the criteria: linearity ($R^2 \geq 0.8$), precision (CV <15%), accuracy (CV <15%) recovery (> 80%), lower limit of detection and quantification (Table 1).

Dissolution profile

The kinetics of dissolution were determined following pharmacopeia parameters at 10, 15, 20, 30, 45, 60 min in 12 independent tests. The mean value at every time point was used to calculate the logarithmic linear regression and the mathematical model of the dissolution profiles, where y is the percentage of dissolved drug and x is time:

$$\text{Stavudine: } y = 0.0097\ln(x) + 3.6246$$

$$\text{Lamivudine: } y = 0.0345\ln(x) + 5.0272$$

$$\text{Zidovudine: } y = 0.0975\ln(x) + 5.6808$$

Similar interpolation accumulation periods in Caco-2 monolayers and cells accumulated area under the curve (AUC) pharmacokinetics in humans and rabbits was performed (Table 2).

Permeability assays in Caco-2 cells

The parameters for the permeability assays in cell monolayers were standardized. In addition to test the integrity of the monolayers by TEER, markers for transcellular and paracellular transport were used, Metoprolol (high permeability) and Mannitol (low permeability), respectively. The Papp of metoprolol was 47.2×10^{-6} cm/seg (SD $\pm 5.5 \times 10^{-6}$, n=5). On the other hand, it was not possible to determine the Papp for mannitol since the concentrations in the recipient compartment were below the limit of detection. The determination of the changes in concentration in the receiver compartment at 15, 30, 45, 60, 90 and 120 min in ten independent tests allowed us to evaluate the indicators of diffusion (Table 3). The data obtained from first order kinetics were adjusted by least squares regression, with a correlation coefficient >0.99, where y is the concentration ($\mu\text{g/mL}$) and x is the time (h):

Table 1. Bioanalytical methods validation.

Parameter	Hanks balanced salt solution			Human plasma		
	Stavudine	Lamivudine	Zidovudine	Stavudine	Lamivudine	Zidovudine
Linearity	$y = 1.061x + 0.019$ $R^2 = 0.9990$	$y = 0.971x - 0.025$ $R^2 = 0.999$	$y = 0.814x + 0.085$ $R^2 = 0.9901$	$y = 1.055x - 0.022$ $R^2 = 0.9958$	$y = 0.942x - 0.055$ $R^2 = 0.995$	$y = 0.567x - 0.016$ $R^2 = 0.9993$
Precision (Coefficient of variation %)	2.1	1.9	2.4	2.8	3.5	1.5
Accuracy (Relative error %)	0.3	0.1	1.3	4.5	0.2	0.2
Low limit of detection ($\mu\text{g/mL}$)	0.0	0.0	0.0	0.0	0.0	0.0
Low limit of quantitation ($\mu\text{g/mL}$)	0.0	0.0	0.1	0.1	0.1	0.0
Recovery (%)	99.1	99.9	97.1	95.6	99.2	99.7

Table 2. Dissolutions profiles and accumulation percent in Caco-2, rabbits and humans.

		Time (h)					
		0.17	0.25	0.33	0.50	0.75	1.00
Zidovudine	Dissolution	83.555	86.924	89.397	93.002	96.752	99.504
	Accumulate Caco-2	0.955	2.102	3.627	7.734	16.392	27.889
	Accumulate AUC Rabbit	2.370	5.040	8.220	15.240	26.070	36.190
	Accumulate AUC Human	2.700	5.800	9.550	18.070	31.480	44.020
Lamivudine	Dissolution	94.831	96.167	97.126	98.495	99.882	100.878
	Accumulate Caco-2	0.744	1.666	2.942	6.544	14.534	25.595
	Accumulate AUC Rabbit	0.750	1.640	2.820	5.860	11.640	18.330
	Accumulate AUC Human	0.170	0.380	0.670	1.460	3.120	5.270
Stavudine	Dissolution	92.362	92.726	92.985	93.352	93.720	93.982
	Accumulate Caco-2	0.760	1.699	2.995	6.637	14.683	25.782
	Accumulate AUC Rabbit	3.640	7.570	11.890	20.660	32.870	43.400
	Accumulate AUC Human	2.230	4.720	7.630	13.940	23.530	32.480

Stavudine: $y = 0.9548\ln(x) + 2.1457$

Lamivudine: $y = 0.9655\ln(x) - 0.0574$

Zidovudine: $y = 0.8391\ln(x) + 1.6946$

These equations were applied to the correlation with dissolution at one hour and the pharmacokinetics in humans and rabbits.

Pharmacokinetics in rabbits

The doses administered to the animals (d4T 0.60 mg/Kg, 3TC 2.13 mg/Kg y AZT 4.14 mg/Kg) were normalized with respect to the doses for human volunteers, to calculate the proportionality between them (rabbit/human). These factors were: d4T 14, 3TC 9.78 y AZT 10.06. The plasma concentration results were used to evaluate the absorption and elimination phases in the logarithm of the concentration versus time curve, where y is the concentration of the drug in plasma and x is the sampling time, in the elimination phase ($R^2 > 0.97$), then:

Stavudine: $y = -0.6906x + 1.3588$

Lamivudine: $y = -0.7271x + 4.2558$

Zidovudine: $y = -0.6206x + 2.9383$

The simulated data obtained using these equations, adjusted by the factor corresponding to human doses, were used in the non-compartmental pharmacokinetic analysis to test the partial and accumulative areas under the curve (AUC_{0-t} , AUC_{Acum}) according to the Wagner-Nelson (Fig. 1), and calculated by:

$$Cp = \frac{F * Dosis * KA}{Vd * (Ka - Ke)} [e^{-Ke*t} - e^{-Ka*t}]$$

Expressed as:

$$Cp = I(e^{-ke*t} - e^{-ka*t})$$

The main pharmacokinetic parameters are described in Table 4. The plasma concentration of the three antiretrovirals reached a maximum value rapidly and later decreased to reach baseline values 6 h after treatment. These results showed the rapid absorption and high permeability of the three APIs. AZT reached the highest bioavailability of the three antiretrovirals.




Figure 1. Pharmacokinetics in animal models.

Pharmacokinetics in humans

The pharmacokinetic profiles were the main reference parameter for the *in vitro-in vivo* correlation (Table 4). The plasma profile of concentration versus time after the administration of a single oral dose of stavudine (40 mg) or lamivudina (150 mg)/zidovudine (300 mg) is shown in Figure 2.

The linear regression of the logarithm of the plasma concentration versus time, provided the mathematical models for the elimination phase ($R^2 > 0.97$). The three antiretroviral tested were rapidly absorbed after oral administration (Tabla 4).

Stavudine: $y = -0.5046x + 0.0649$

Lamivudine: $y = -0.2595x + 2.4725$

Zidovudine: $y = -0.9678x + 0.9018$

In vitro-in vitro correlations

Dissolution versus permeability. The percentages of concentration changes between zero and one hour (maximum time of dissolution) and the changes in concentration in the recipient compartment in the permeability test were compared (Table 2). The linear regression mathematical models showed that the dissolution data are optimal to predict permeability by diffusion ($R^2 > 0.80$).

Stavudine: $y = 14.581x - 1,350, R^2 = 0.8368$

Lamivudine: $y = 3.8844x - 371.6, R^2 = 0.8401$

Zidovudine: $y = 1.6163x - 138.14, R^2 = 0.8655$

Table 3. Diffusion parameters in Caco-2 cells monolayers.

Parameter*	Units	Stavudine	Lamivudine	Zidovudine
$P_{app} \times 10^{-6}$	cm/sec	6.4 ± 1.8	7.0 ± 2.0	20.3 ± 4.7
Flujo (J)	µg/cm ² /min	0.081 ± 0.003	0.041 ± 0.005	0.063 ± 0.004

*Mean ± SD (n= 10).
 P_{app} = Apparent permeability coefficient




Figure 2. Pharmacokinetics in humans.




Figure 3. Correlation cumulative AUC in humans versus animal model.

Where y is the AUC accumulative percentages in Caco-2 cells and x is the percentage of dissolution. These functions can be implemented to predict the quality of drugs in terms of permeability and the quality of excipients from different sources during the manufacturing process.

In vivo-in vivo correlations

Rabbit vs. humans. The cumulative areas under the curve were correlated and a statistical analysis by least squares was applied (Fig. 3). A high correlation between the pharmacokinetic profiles in humans and in the animal model was observed (stavudine $R^2= 0.987$, lamivudine $R^2= 0.885$ and zidovudine $R^2= 0.989$). The AUC_{0-t} for zidovudine in both species was proportional to the dose. However, for lamivudine even though the ratio rabbit/human was ten, the AUC_{0-t} only exceeded the value in humans by a factor of two. For stavudine, the dose ratio was 15 times higher for rabbits than humans, but the AUC_{0-t} in rabbits was only two and a half times the AUC_{0-t} in humans.

The C_{max} values presented the largest interspecies differences regarding the fraction of drug absorbed, therefore the use of

this parameter to predict the behavior of these drugs is not recommended. The time to reach the maximum concentration (T_{max}) of zidovudine was two times higher in humans than in rabbits (0.75 h and 0.33 h, respectively), while for lamivudine and stavudine the values were similar (Table 4). Consequently, for these drugs T_{max} in rabbits was directly related to the expected results in humans. The comparison of the *in vivo* results, in rabbits and humans for AUC_{0-t} , was based on the plasma profiles and patterns of elimination in the curve of the logarithm of concentration versus time for simulated changes in the same periods (Wagner Nelson Method).

Correlation of the accumulative percentages of AUC in humans versus rabbits

The mathematical models of the linear correlation and the corresponding factors (R^2) to the least squares regression were:

Stavudine: $y = 0.9709x + 7.6027, R^2 = 0.987$
 Lamivudine: $y = 0.8562x - 9.3888, R^2 = 0.885$
 Zidovudine: $y = 0.9838x - 3.4354, R^2 = 0.988$

Table 4. Pharmacokinetics parameters in the animal model and humans

Product		Rabbit pharmacokinetic			Human pharmacokinetic		
		Zidovudine	Lamivudine	Stavudine	Zidovudine	Lamivudine	Stavudine
C_{max}	µg/mL	12.17	3.31	3.15	2.12	0.94	0.73
T_{max}	h	0.75	1.00	0.33	0.33	1.00	0.50
$T_{1/2}$	h	1.12	0.95	1.00	0.72	2.68	1.37
$AUC_{(0-t)}$	h*µg/mL	25.17	6.87	4.38	2.16	3.51	1.67
$AUC_{(0-\infty)}$	h*µg/mL	26.00	6.99	4.90	2.16	3.51	1.67
$AUMC_{(0-t)}$	µg-h*h/mL	41.34	11.62	4.97	3.02	10.41	3.02
$AUMC_{(0-\infty)}$	µg-h*h/mL	47.71	12.53	7.10	3.02	10.41	3.02

C_{max} = maximum concentration
 T_{max} = time required to reach the maximal concentration
 AUC = area under the curve in time
 AUMC = Area under the first moment curve

X values represent cumulative AUC in rabbits interpolated for cumulative AUC in humans at the same period for equivalent doses. The correlation factors demonstrated the ability of the rabbit species to predict bioavailability in humans due to the amount of absorbed and accumulated drug over time, with a probability close to or greater than 90%. These mathematical models exceed the biological variability analysis and inter-species differences because each subject responded comprehensively combining the physiological properties of the animal and the human subject under test conditions.

In vitro-in vivo correlations

Dissolution versus AUC_{0-t} in Humans. The dissolution profiles and pharmacokinetics in animals and humans were compared (Table 2). Direct, exponential correlation between the percentage of the drug dissolved *in vitro* and cumulative AUC in humans was found ($R^2 > 0.99$).

$$\text{Stavudine: } y = 1.4842^{e^{0.5376x}}$$

$$\text{Lamivudine: } y = 0.0902^{e^{0.6906x}}$$

$$\text{Zidovudine: } y = 1.7444^{e^{0.5619x}}$$

In these equations x represents dissolution percentage values and y represents *in vivo* projected AUC for the same period. The Pharmacokinetic data in the animal model also showed satisfactory results with exponential models and correlation factors greater than 0.98. A direct exponential relationship between the percent of dissolution and the amount of drug available in the blood plasma was used to predict the effectiveness of the absorption processes based on the data of *in vitro* dissolution percentages.

Permeability versus AUC in humans. Cumulative AUC values in the Caco-2 system were correlated with AUC values *in vivo* in the first two hours since the permeability test was performed for two hours. A directly proportional relation for lamivudine was found, while for stavudine and zidovudine the relation was logarithmic (Fig. 4). The following functions expressed the direct relationship between the percentage of transferred drug in Caco-2 cells and the post-administration cumulative AUC percentage.

$$\text{Stavudine: } y = 11.820\ln(x) - 2.3697 \quad R^2 = 0.9305$$

$$\text{Zidovudine: } y = 16.488\ln(x) - 7.2008 \quad R^2 = 0.9332$$

$$\text{Lamivudine: } y = 0.172(x) + 0.3678 \quad R^2 = 0.9961$$

The results of the comparisons in the animal model were equally satisfactory with exponential functions and correlation factors greater than 0.90.




Figure 4. Correlation *in vitro* permeability versus *in vivo* absorption.

Multiple Linear Regressions

Pharmacokinetics in humans vs dissolution percent and permeability in Caco-2 cells. The final interpretation of the relationship between *in vitro* results (dissolution percent and the amount of drug diffused through Caco-2 monolayers), and the amount of drug accumulated over time in humans was performed by multiple linear regressions with a confidence interval of 95% ($p < 0.05$) for the following functions:

Independent variables: Dissolution percent and cumulative AUC in Caco-2.

Dependent Variable: cumulative AUC in humans at the first hour post-absorption.

Stavudine: R^2 0.986

$$AUC_{AcuHum} = 2.681 + (0.0149 * \text{Dissolution percent}) + (1.170 * AUC_{AcuCaco-2})$$

Lamivudine: R^2 0.999

$$AUC_{AcuHum} = -1.713 + (0.0185 * \text{Dissolution percent}) + (0.202 * AUC_{AcuCaco-2})$$

Zidovudine: R^2 0.991

$$AUC_{AcuHum} = 2.255 + (0.0232 * \text{Dissolution percent}) + (1.488 * AUC_{AcuCaco-2})$$

Similar results with correlations greater than 0.97 were obtained from the multiple regressions, considering the same variables in the animal model.

Discussion

Regulations require assessing the quality of drugs through *in vivo* bioavailability and bioequivalence tests in healthy adult humans. This study proved the validity of applying surrogate *in vitro* tests to reduce the costs and ethical risks associated to the inclusion of humans in research, as long as solid scientific evidence support the substitution. These tests are based on the solubility and permeability properties of the active pharmaceutical ingredients, according to the biopharmaceutics classification system (BCS)³. Stavudine, lamivudine and zidovudine are Type I compounds, highly soluble and highly permeable⁸. Type I drugs in immediate release oral products, can be waived from human studies, however, currently their quality is demonstrated by *in vivo* bioavailability and bioequivalence tests.

Physicochemical assessment and dissolution test

The analyzed products meet the quality specifications for drug content, dose uniformity and dissolution profile according to the United States pharmacopeia (USP34, NF29, 2011) and related documents⁹⁻¹³. In less than 20 min 99.0% of lamivudine, 91.2% of zidovudine and 93.5% of stavudine were dissolved. The solubility test supported the recommendation of exemption from *in vivo* bioequivalence studies for dosage forms of immediate release like stavudine, lamivudine and zidovudine^{14,15}. The dissolution profile confirmed that 81.8% of zidovudine was released from the tablets in the first 10 minutes and 93.4% of lamivudine. The capsules of stavudine released more than 90.0% of the API in the first 15 min.

Permeability tests in Caco-2 cells

Metoprolol and mannitol were used as high and low permeability standards respectively and the results were concordant with other studies and FDA guidelines^{16,17}. This support the suitability of our *in vitro* system to discriminate between high and low permeability

compounds. The results obtained when testing stavudine and lamivudine were very similar and fit the definition of highly permeable drugs. The permeability of zidovudine was three times higher than the permeability of stavudine and lamivudine which is related to its physicochemical properties of lipophilicity. This methodology is in compliance with the requirements of the guidelines for *in vitro* test for the evaluation of solubility and permeability properties established in the BCS and other publication in the field¹⁸⁻²¹. The functionality of the Caco-2 system was confirmed by calculating the apparent permeability coefficient (Papp), permeability coefficient (P) and flux coefficient (J).

Pharmacokinetic studies

The rabbit animal model proved to be an efficient way to evaluate absorption process according to biological and biochemical properties that are similar to humans, therefore supporting its use in pre-clinical research²²⁻²³. The guidelines for good laboratory practices and use of animals in bioavailability and bioequivalence studies were followed²⁴⁻²⁹. The three drugs reached the maximum plasma concentration in an hour or less, being around 20 min for stavudine. The half-life time in rabbits for lamivudine was 0.95 h, shorter than the experimental value in humans (2.68 h), it was slightly longer for zidovudine 1.12 h (0.72 h) and shorter for stavudine 1.0h (1.37 h).

The human studies were taken as references for quality in terms of plasma concentration and AUC for a period of 12 h³⁰⁻³³. The evaluated parameters were: maximum concentration (C_{max}), area under the curve in time (AUC_{0-t}) and time required to reach the maximal concentration (T_{max}).

This study demonstrated the bioavailability of the dosage forms zidovudine 300 mg/lamivudine 150 mg tablets and stavudine 40 mg capsules manufactured by Humax Pharmaceutical S.A, and the compliance with quality standards according to the dissolution properties, drug content and other physicochemical properties described for these dosage forms. The diffusion and permeability capacity of the compounds was confirm using the cell monolayer model and a direct correlation with the pharmacokinetic of absorption in the animal model and humans was found. The analytical methods and validated procedures applied to *in vitro* tests demonstrated the direct correlation with the results obtained in the pharmacokinetic studies, with correlation coefficients greater than 0.85.

Conclusions

This study achieve the goal to implement analytical methodologies, that are commonly applied in the discovery and development of new drugs, to measure the physical and biological properties of the compounds that correlate with the bioavailability studies in humans, according to the principles of IVIVC. In all the comparisons the linear regression by the least square method provided correlation factors close or greater than 0.9, the tested comparisons were:

in vitro-in vitro: Permeability-Dissolution

in vitro-in vivo: Dissolution-Pharmacokinetics

in vitro-in vivo: Permeability-Pharmacokinetics

in vivo-in vivo: Pharmacokinetics Animal Model-Human

The results of this study support the proposal to revise the regulatory requirements in force in Colombia, related to *in vivo* tests like bioequivalence studies for immediate release products with APIs classified as BCS-I, specifically antiretroviral nucleoside reverse transcriptase inhibitors.

It is proposed to improve the capacity of the pharmaceutical industry to standardize *in vitro* and *in vivo* (rabbits) methods, complementary to the dissolution tests, in order to validate the results between them and to give strength and power, which is essential for quality assurance for *in vivo* behavior.

Conflict of interest:

The authors have declared that no competing interests exist.

Funding:

This research was financed by COLCIENCIAS grant 2209-327-18510 and HUMAX Pharmaceutical S.A. contract 420-2006.

References

1. Cook J, Addicks W, Wu YH. Application of the biopharmaceutical classification System in Clinical Drug Development, An Industrial View. AAPS J. 2008; 10(2): 306–10.
2. Emami J. In vitro - in vivo correlation: from theory to applications. J Pharm Pharm Sci. 2006; 9(2): 169–89.
3. Amidon KS, Langguth P, Lennernas, Yu HL, Amidon GL. Bioequivalence of oral products and the Biopharmaceutics Classification System. Clin Pharmacol Ther. 2011; 90(3): 467–70.
4. Ministerio de Protección Social . Ley 84 de 1989. Por la cual se adopta el Estatuto Nacional de Protección de los Animales y se crean unas contravenciones y se regula lo referente a su procedimiento y competencia. Bogotá, Colombia.
5. Ministerio de Protección Social . Resolución 008430 de 1993. Por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud. Bogotá, Colombia.
6. WHO. Regional Publications Eastern Mediterranean Series 30. Practical Guide for Health Researchers. 2004.
7. FDA. Center for Drug Evaluation and Research . Guidance for the industry. Bioanalytical Method Validation. EEUU: 2001.
8. Joseph MC, Chi-Yuan W, Leslie ZB. Predicting drug disposition, absorption/ elimination/ transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008;60(6):717–733.
9. WHO. Lamivudine. Final text for addition to The International Pharmacopoeia. (QAS/05.123/FINAL) 2006:5–5.
10. Strauch S, Jantravid E, Dressman JB, Junginger HE, Kopp S, Midha KK, et al. Biowaiver monographs for immediate release Solid Oral Dosage Forms: Lamivudine. J Pharm Sci. 2011; 100: 2054–63.

11. NIH. HHS. National Library of Medicine. Retrovir (zidovudine). Current Medication Information, Daily Med. EEUU: December . 2011.
12. NIH. HHS. National Library of Medicine . Stavudine capsule (Mylan Pharmaceuticals Inc). Current Medication Information, Daily Med. EEUU: January . 2012.
13. WHO . Forty-seventh report of the WHO Expert Committee on specifications for pharmaceutical preparations. Technical Report Series 981. WHO; 2013. pp. 202.
14. Department of Health and Human Services,FDA . Office of Generic Drugs Division of Bioequivalence Update Frequency: Quarterly. EEUU: January 11, . 2010.
15. Corti G, Maestrelli F, Cirri M, Zerrouk N, Mura P. Development and evaluation of an in vitro method for prediction of human drug absorption II. Demonstration of the method suitability. Eur J Pharm Sci. 2006;27(4):354–362.
16. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev. 2001;46(1-3):27–43.
17. Volpe DA. Application of method suitability for drug permeability classification. AAPS J. 2010;12(4):670–678.
18. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. EEUU: August . 2000.
19. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP) Guideline on the investigation of bioequivalence. CPMP/EWP/QWP/1401/98 Rev. 1/ Corr. London: January . 2010.
20. Polli JE, Abrahamsson BSI, Yu LX, Amidon GL, Baldoni JM, Cook JA, et al. Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond. AAPS J. 2008;10(2):373–379.
21. Kumar KV, Swathi Ki, Mamatha RB, Chandramouli R. Caco-2 Cell Lines in Drug Discovery - An Updated Perspective. J Basic Clin Pharm. 2010;1(2):63–69.
22. National Research Council (US) Committee to Update Science, Medicine, and Animals. Science, Medicine, and Animals. Washington (DC): National Academies Press (US); 2004. Committee to Update Science, Medicine, and Animals
23. Department of Health and Human Services . ACPS Meeting Achieving and demonstrating "Quality by Design" with respect to drug release/dissolution performance for conventional or immediate release solid oral dosage forms. EEUU: October . 2005.
24. WHO . Good Laboratory Practices Training Manual. UNDP/ World Bank/WHO Special Programme for Research and Training in Tropical Disease (TDR); 2001. pp. 142.
25. Department of Health and Human Services.Food and Drug Administration. Center for Drug Evaluation and Research (CDER) Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. 2003.
26. WHO Marketing Authorization of Pharmaceutical Products with Special Reference to Multisource (generics) Products. (WHO/DMP/RGS/98.5) 1998.
27. The European Agency for the Evaluation of Medicinal Products. Evaluation of Medicines for Human Use. 2000.
28. Políticas de la Asociación Médica Mundial. Declaración de la Asociación Médica Mundial sobre el Uso de Animales en la Investigación Biomédica. Hong Kong: 1989.
29. Tempelman RJ. Experimental design and statistical methods for classical and bioequivalence hypothesis testing with an application to dairy nutrition studies. J Anim Sci. 2004; 82 Suppl: E162–72.
30. Khandave SS, Onkar SV, Sawant SV, Joshi SS. Evaluation of performance of the truncated area under curve (AUC) as a primary pharmacokinetic parameter in bioequivalence studies. J Bioequiv Availab. 2010; 2(4): 77–80.
31. Shargel L, Wo-Pong S, Yub CA. Applied biopharmaceutics and pharmacokinetics. Fifth Edition. United States of America: McGraw Hill; 2005.
32. WHO Annex 8 Proposal to waive in vivo bioequivalence requirements for the WHO Model List of Essential Medicines immediate release, solid oral dosage forms. 2006: 391–437. Technical Report Series No 937.
33. Vacca GCP, Fitzgerald JF, Bermudez JAZ. Definición de medicamento genérico: un fin o un medio. análisis de la regulación en 14 países de la región de las Américas. Rev Panam Salud Publica. 2006; 20(5): 314–23.